Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Michael Laska is currently VP of Process Development & Manufacturing at a Flagship Pioneering New Company, continuing his career advancing novel therapeutic modalities into the Clinic. Previously he was VP of CMC Development & Manufacturing at Casebia Therapeutics responsible for development and manufacture of gene-editing therapies for diverse indications. Before that he was Head of Process Development at Moderna Therapeutics (Cambridge, MA), where he managed process development and scale-up of Moderna’s innovative messenger RNA platform for therapeutics and vaccines. Michael began his career at Merck Research Laboratories, Merck & Co., Inc. (West Point, PA), taking on increasing leadership within the BioProcess Research & Development organization responsible for vaccine and biologics development. During his career he has led groups of engineers and scientists in the development of processes for diverse vaccine and biologic product candidates; including process scale-up and transfer for clinical and commercial production. His experience includes leading multi-functional teams through the evolution of product candidates along the path of clinical development toward regulatory approval. He received a BS in Chemical Engineering from the University of Virginia. He received a MS in Chemical Engineering Practice (MSCEP) and PhD in Chemical Engineering from the Massachusetts Institute of Technology.